Kyle Piskel, the Chief Financial Officer of Adaptive Biotechnologies Corp (NASDAQ: ADPT), sold 3,115 shares of the company on May 18, 2026, for a total of $40,619. This transaction was executed at a price of $13.04 per share, primarily to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs). Following this sale, Piskel holds 256,725 shares of the company. Adaptive Biotechnologies' stock has seen significant growth, currently trading at $13.95, reflecting a nearly 50% increase over the past year, despite the company remaining unprofitable. In the last twelve months, Adaptive Biotechnologies reported revenues of $295 million, marking a 56% growth. In its first quarter of 2026, the company surpassed revenue expectations by achieving $70.9 million, exceeding the forecast of $60.89 million by approximately 16.4%. This growth has been largely driven by advancements in its Minimal Residual Disease (MRD) business. While the stock's valuation is under scrutiny, the company's strong financial performance continues to attract investor interest.